Katarina Miljević/LinkedIn
Jul 15, 2026, 13:43
Katarina Miljević: New Insights into Recombinant tPA and FXI Inhibition at ISTH 2026
Katarina Miljević, Postdoctoral Research Scientist at the Department of Clinical Pharmacology, Medical University of Vienna, shared a post on LinkedIn:
“I was delighted to present two posters at the ISTH 2026 Congress in Paris, highlighting research from the Department of Clinical Pharmacology MedUni Vienna, focusing on:
- Pharmacokinetic and pharmacodynamic equivalence of recombinant tPA products
- FXI inhibition with cenvacibart and its effects on hemodialysis circuit clotting
Grateful to all collaborators and co-authors who contributed to these projects.
Looking forward to the discussions and future research opportunities.”
Stay updated with Hemostasis Today.
-
Jul 15, 2026, 14:15Sarah Richardson: Today, I Ask You to Stand with the Bleeding Disorders Community
-
Jul 15, 2026, 14:03Anna Randi: Imperial College London’s Vascular Haemostasis and Thrombosis Team Shines at ISTH 2026
-
Jul 15, 2026, 13:53Akhil Antony Konkoth: Galectin-9 Emerges as a Key Mediator of Venous Thromboinflammation
-
Jul 15, 2026, 13:48Sabine Eichinger: New Insights into Recurrence Risk After Provoked VTE at ISTH 2026
-
Jul 15, 2026, 13:44Shirley D’Sa: Vitamin B6 Offers a New Clue in the POEMS Syndrome Puzzle
-
Jul 15, 2026, 13:31Sandrine Meunier: ISTH 2026 Highlights Consensus on Pediatric Hemostatic Assessment
-
Jul 15, 2026, 13:20Mauricio Bordonaba: Reflecting on ISTH 2026 and Our Commitment to a Truly Free Hemophilia Life
-
Jul 15, 2026, 07:15Sandrine Horman: Back From an Inspiring Week at ISTH 2026
-
Jul 15, 2026, 06:55Christopher Devany: Great to Be Here in Paris for the ISTH 2026